CLOSEOUT LETTER
Pharmcore Inc. dba Hallandale Pharmacy MARCS-CMS 605569 —
- Delivery Method:
- Via Email
- Product:
- Drugs
- Recipient:
-
Recipient NameDavid G. Rabbani
-
Recipient TitleOwner and President
- Pharmcore Inc. dba Hallandale Pharmacy
2666 SW 36th St
Fort Lauderdale, FL 33312-5005
United States-
- drabbani@hallandalerx.com
- Issuing Office:
- Office of Pharmaceutical Quality Operations, Division II
United States
Dear Mr. Rabbani :
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Case #605569), issued on March 11, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Caroline Le, PharmD.
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II
cc:
VIA E-MAIL
Ms. Leilani Bellieni, QA Director
Pharmcore, Inc. dba Hallandale Pharmacy
2666 Southwest 36th Street
Fort Lauderdale, Florida 33312
leilani@hallandalerx.com